<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743079</url>
  </required_header>
  <id_info>
    <org_study_id>20080810</org_study_id>
    <nct_id>NCT01743079</nct_id>
  </id_info>
  <brief_title>Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B</brief_title>
  <official_title>The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Discovery LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing YouAn Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of telbivudine and
      lamivudine use during late pregnancy for the prevention of HBV perinatal transmission in
      highly viraemic mothers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study enrolls HBV mono-infected pregnant women cohorts managed in outpatient
      clinics/delivery unit at YouAn Hospital in Beijing. Subjects are prospectively followed from
      gestation week 26 to postpartum week 52. Treatment na√Øve mothers with HBV DNA &gt; 6 log10 c/mL
      and normal ALT are eligible. Mothers with abnormal fetus, cirrhosis or evidence of
      hepatocellular carcinoma (HCC) are excluded. At gestation week 28, mothers will receive
      telbivudine (LdT) 600 mg per day or lamivudine (Lam) 100 mg per day until postpartum 4 or no
      treatment as per their preference. All infants will receive standard immunoprophylaxis. Data
      is collected from patient records using data extraction forms. Primary endpoints are vertical
      transmission rates at infants' age of 52 week and the safety of telbivudine or lamivudine
      use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety on fetal exposure of telbivudine and lamivudine and vertical transmission rate from mother to child</measure>
    <time_frame>From gestation week 26 to postpartum week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of mothers with serum HBV DNA level reduction, ALT within normal range and HBeAg and/or HBsAg negativity with or without seroconversion</measure>
    <time_frame>From gestation week 26 to pastpartume week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Late Pregnancy</condition>
  <condition>Transmission</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antiviral treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>LdT 600mg QD</description>
    <arm_group_label>Telbivudine</arm_group_label>
    <other_name>LdT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>LAM 100mg QD</description>
    <arm_group_label>Lamivudine</arm_group_label>
    <other_name>LAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 20-40 years old

          2. HBsAg, HBeAg positive and HBV DNA &gt;6 log10 copies/ml

          3. Gestational age: 26-28 weeks with normal fetus

          4. Willing to consent for the study

        Exclusion Criteria:

          1. Elevated ALT

          2. Antiviral treatment experience patients

          3. Co-infection with HAV, HCV,HDV, HIV

          4. Concurrent treatment with immune modulators, cytotoxic drugs, or steroids

          5. Clinical signs of threatened miscarriage in early pregnancy

          6. Clinical evidence of cirrhosis and/or hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Calvin Pan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Liver Diseases, Mount Sinai School of Medicine, Flushing, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing YouAn Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing YouAn Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Telbivudine</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

